Rationale, discovery and clinical development of NEO-201
Most monoclonal antibody cancer therapies are developed for known targets and are commercially approved for...
17Dec
06Nov
SITC 2019
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...
27Oct
Immuno-Oncology Europe 2019
Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes
Presented by Dr. Philip Arlen
President and...
15Oct
Novel Targets Of Neoantigens In Monoclonal Antibodies
Philip M. Arlen, M.D.
Summary:
Target is broadly expressed in multiple solid tumors. Exhibits both ADCC and CDC...
06Aug
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION – Cambridge Healthtech Institute August 8-9, 2019
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION, PANEL DISCUSSION:...
30Apr
2019 ASCO Annual Meeting
Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with...